Active and passive immunotherapy for neurodegenerative disorders.

By David L. Brody, D. Holtzman. Annual Review of Neuroscience, 2008

829 citations recorded by the source corpus.

Subfields: Cell Biology, Neurology, Physiology

View Paper: https://www.semanticscholar.org/paper/d965eca60b28bf65820c9f5da2bf3e28703dcaa0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. Martin Citron
2. D. Holtzman
3. L. Mucke

In Neurology

1. D. Holtzman
2. Martin Citron
3. John C. Morris
4. A. Goate
5. L. Mucke

In Physiology

1. D. Holtzman
2. A. Goate
3. John C. Morris
4. Martin Citron
5. L. Mucke
6. Sokratis G. Papageorgiou
7. K. Yiannopoulou
8. J. Long

Citations in the corpus

• Current and future treatments for Alzheimer’s disease (2013, background): “Most of these vaccines are now being tested in phase I and II trials: the CAD-106 trial led by Novartis/Cytos (Basel, Switzerland) and the V950 trial initiated by Merck (Whitehouse Station, NJ, USA) [Brody and Holtzman, 2008].”
• Alzheimer's disease: strategies for disease modification (2010, background): “Discussions about the efficacy of immunotherapy also focus on Elan and Wyeth's AN1792, an active immunization against synthetic Aβ 1–42 peptide, and the first Aβ directed immunotherapy to enter Phase II trials (for a review see Ref”
• The Many Faces of Tau (2011, background): “If there is an equilibrium between intracellular and extracellular tau, clearance of tau/antibody complexes from the extracellular space may ultimately lower intracellular tau levels (Brody and Holtzman, 2008; Sigurdsson, 2009).”
• Alzheimer’s Disease: The Challenge of the Second Century (2011, background): “It appears that anti-Ab antibodies account for the beneficial effects in these immunization studies probably through several mechanisms involving clearing soluble and aggregated Ab via cellular and noncellular mechanisms, as well as by blocking Ab toxicity (190).”
• Excitotoxicity: bridge to various triggers in neurodegenerative disorders. (2013, background): “Recent decades have witnessed fast development of the biochemical theories of neuronal death and survival and in consequence new approaches to the treatment of neurodegenerative diseases based on a cell and a gene therapy have been proposed (Brody and Holtzman (2008)).”